![Jeffrey Tabor](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Jeffrey Tabor first degree
Entity | Entity type | Industry | |
---|---|---|---|
Pana Bio, Inc.
![]() Pana Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Pana Bio, Inc. is an American biotechnology company that focuses on the development and delivery of therapeutic molecules. The CEO of the company is David Yu Zhang.
3
| Holding Company | Miscellaneous Commercial Services | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Jeffrey Tabor via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Torus Biosystems, Inc.
![]() Torus Biosystems, Inc. Miscellaneous Commercial ServicesCommercial Services Torus Biosystems, Inc. engages in the provision of biotechnology services. It performs DNA testing for scientific and medical research purposes. The company was founded in 2019 and is headquartered in Brookline, MA. | Miscellaneous Commercial Services | Founder | |
Biostate AI, Inc.
![]() Biostate AI, Inc. Packaged SoftwareTechnology Services Biostate AI, Inc. develops AI software to eliminate trial and error in medicine. | Packaged Software | Director/Board Member | |
Avenge Bio, Inc.
![]() Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
United States | 4 |
Sectoral
Commercial Services | 2 |
Technology Services | 2 |
Health Technology | 2 |
Operational
Director/Board Member | 6 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Chief Executive Officer | 1 |
Most connected contacts
Insiders | |
---|---|
David Yu Zhang | 3 |
Omid Veiseh | 2 |
Robert Britton | 1 |
- Stock Market
- Insiders
- Jeffrey Tabor
- Company connections